3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Breast Neoplasms
13
Rectal Neoplasms
10
Esophageal Neoplasms
7
Colorectal Neoplasms
7
Stomach Neoplasms
6
Esophageal Squamous Cell Carcinoma
6
Uterine Cervical Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Adenocarcinoma Of Esophagus
5
Squamous Cell Carcinoma of Head and Neck
4
Neuroblastoma
4
Neoplasm Metastasis
4
Nasopharyngeal Carcinoma
4
Colonic Neoplasms
4
Sarcoma
3
Pancreatic Neoplasms
3
Lung Neoplasms
3
Liposarcoma
3
Inflammatory Breast Neoplasms
3
Head and Neck Neoplasms
3
Fallopian Tube Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Prostatic Neoplasms
2
Peritoneal Neoplasms
2
Ovarian Neoplasms
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Multiple Myeloma
2
Melanoma
2
Hemangiosarcoma
2
Hemangiopericytoma, Malignant
2
Interventions
Dexamethasone
20
Melphalan
13
Thalidomide
10
Bortezomib
10
Lenalidomide
8
Cyclophosphamide
8
Prednisone
6
Filgrastim
6
Doxorubicin
6
Vincristine
5
Epoetin Alfa
5
pomalidomide
3
Zoledronic Acid
3
Peripheral Blood Stem Cell Transplantation
3
Idarubicin
3
carfilzomib
2
Vorinostat
2
Radiotherapy
2
Interferon-alpha
2
Granulocyte Colony-Stimulating Factor
2
Early Intervention, Educational
2
Darbepoetin alfa
2
Carmustine
2
Calcium Dobesilate
2
Busulfan
2
valspodar
1
sargramostim
1
oblimersen
1
liposomal doxorubicin
1
isatuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms, Plasma Cell
×
Neoadjuvant Therapy
×
Clear all
NCT01554852
2018-06-11
Myeloma XI
University of Leeds
Phase 3
Unknown
4,420 enrolled